```html

Xanthine Phosphoribosyltransferase Deficiency (XPTR Deficiency)

Overview

Xanthine phosphoribosyltransferase (XPRT) deficiency is an extremely rare inherited metabolic disorder that impairs the body’s ability to recycle purines‑based nucleotides. The enzyme XPRT, also known as xanthine phosphoribosyltransferase, normally converts xanthine into its nucleotide form (xanthosine monophosphate) as part of the purine salvage pathway. When this enzyme is absent or severely reduced, xanthine accumulates in the blood and is excreted in the urine, leading to a cascade of clinical problems.

Who it affects: The condition follows an autosomal recessive inheritance pattern, meaning that a child must inherit two defective copies of the HPRT1‑related gene (the gene that encodes XPRT) to develop the disease. Both males and females are equally affected.

Prevalence: Fewer than 1 in 1 000 000 individuals worldwide have been reported in the medical literature. Most cases have been identified in families of Middle‑Eastern, South‑Asian, or Mediterranean descent, although isolated cases appear in other ethnic groups (NIH, 2022).

Symptoms

The clinical picture of XPRT deficiency can range from virtually asymptomatic to severe multisystem disease. Symptoms usually appear in infancy or early childhood, but some patients remain undiagnosed until adulthood.

Neurologic

• Developmental delay – lag in speech, motor milestones, and cognitive milestones.
• Intellectual disability – mild to moderate impairment in learning and problem‑solving.
• Seizures – focal or generalized, often triggered by metabolic stress.
• Movement disorders – ataxia, dystonia, or tremor.

Renal / Urinary

• Kidney stones (urolithiasis) – predominantly composed of xanthine, which is poorly soluble.
• Hematuria – blood in the urine due to stone irritation.
• Recurrent urinary tract infections (UTIs) – secondary to obstruction.

Gastrointestinal

• Abdominal pain related to stone passage.
• Vomiting or nausea during acute stone events.

Hematologic / Metabolic

• Elevated serum and urinary xanthine levels.
• Low or absent uric acid (hypouricemia) because xanthine is not converted to uric acid.
• Possible mild anemia due to chronic renal impairment.

Other

• Growth retardation (height & weight below percentile curves).
• Fatigue and exercise intolerance.
• Skin lesions are rare but have been reported in some patients with chronic renal disease.

Causes and Risk Factors

The root cause is a pathogenic variant in the HPRT1 gene (previously thought to encode only hypoxanthine‑guanine phosphoribosyltransferase). Certain mutations abolish the enzyme’s activity, preventing the conversion of xanthine to xanthosine monophosphate. Because the salvage pathway is blocked, excess xanthine is shunted toward the kidneys where it precipitates.

Risk factors are largely genetic:

• Both parents are carriers of a pathogenic HPRT1 mutation.
• Consanguineous marriage increases the chance of inheriting two defective copies.
• Family history of unexplained kidney stones, neurological problems, or previously diagnosed XPRT deficiency.

Non‑genetic contributors (e.g., dehydration, high‑purine diet) can **exacerbate** stone formation but do not cause the disorder.

Diagnosis

Because the condition is rare, clinicians usually consider it after encountering a combination of unexplained neuro‑developmental issues and xanthine‑rich kidney stones.

Laboratory Tests

• Serum chemistry – low uric acid (< 2 mg/dL) with normal creatinine unless renal damage is present.
• Urine analysis – high xanthine concentration (often > 500 µmol/L) measured by high‑performance liquid chromatography (HPLC) or mass spectrometry.
• Enzyme activity assay – measures XPRT activity in cultured fibroblasts or leukocytes; activity <10 % of normal is diagnostic.
• Genetic testing – targeted sequencing or a multigene panel for purine‑metabolism disorders confirms pathogenic HPRT1 variants (CDC, 2023).

Imaging

• Renal ultrasound – detects echogenic stones, hydronephrosis, or chronic parenchymal changes.
• CT scan (non‑contrast) – gold standard for stone size, location, and composition.
• Brain MRI may be ordered if seizures or developmental delays are prominent, to rule out other structural causes.

Differential Diagnosis

Conditions that can mimic XPRT deficiency include:

• Lesch–Nyhan syndrome (deficient HPRT enzyme but with hyperuricemia and self‑injurious behavior).
• Hereditary or primary hyperoxaluria.
• Other inborn errors of purine metabolism (e.g., adenine phosphoribosyltransferase deficiency).

Treatment Options

There is currently no cure, but several strategies reduce xanthine buildup, prevent stone formation, and manage neurologic symptoms.

Medical Management

• Hydration – Aim for >2 L of fluid intake per day (adjusted for age and renal function) to keep urine dilute (specific gravity < 1.010).
• Low‑purine diet – Limit foods high in adenine, guanine, and xanthine precursors (e.g., organ meats, sardines, anchovies, legumes). A registered dietitian experienced in metabolic disorders should design the plan.
• Alkalinization of urine – Sodium bicarbonate or potassium citrate to keep urine pH 6.5–7.0; alkalinity improves xanthine solubility.
• Allopurinol or Febuxostat – Paradoxically, these xanthine oxidase inhibitors increase xanthine levels and are **contraindicated**; they are listed here to avoid a common medication error.
• Enzyme replacement therapy (experimental) – Early‑phase clinical trials are exploring recombinant XPRT delivered via viral vectors; not yet FDA‑approved (NIH, 2020).

Procedural Interventions

• Stone removal – Extracorporeal shock‑wave lithotripsy (ESWL), ureteroscopy, or percutaneous nephrolithotomy, depending on stone size.
• Stent placement – Temporary ureteral stents relieve obstruction during acute episodes.
• Renal transplantation – Considered for end‑stage renal disease; does not correct the metabolic defect, so ongoing metabolic management remains essential.

Neurologic Symptom Management

• Antiepileptic drugs (AEDs) tailored to seizure type – levetiracetam, valproic acid, or lamotrigine are commonly used.
• Early intervention services (speech, occupational, and physical therapy) improve developmental outcomes.
• Behavioral therapy and educational accommodations for intellectual disability.

Living with Xanthine Phosphoribosyltransferase Deficiency

While the diagnosis is lifelong, many patients lead productive lives with appropriate care.

Daily Management Tips

• Fluid tracking – Use a water‑intake app or a daily log to ensure adequate hydration.
• Urine monitoring – Test strips for specific gravity can help keep urine dilute; record results weekly.
• Dietary vigilance – Keep a list of low‑purine foods; avoid “cheat days” that could precipitate stone formation.
• Medication review – Regularly discuss all prescriptions and OTC drugs with your pharmacist to avoid xanthine‑raising agents.
• Regular follow‑up – Kidney ultrasound every 12 months, neuro‑developmental evaluation annually, and biochemical labs every 6 months.
• Family planning counseling – Genetic counseling is recommended for affected individuals considering children.

Psychosocial Support

Connecting with rare‑disease groups (e.g., RareConnect, ORPHANET) provides emotional support and practical advice. Schools should receive a written plan outlining accommodations for learning difficulties.

Prevention

Because XPRT deficiency is genetic, primary prevention is limited to **carrier screening** and **pre‑conception counseling** in high‑risk families. For carriers, prenatal testing (chorionic villus sampling or amniocentesis) can identify an affected fetus.

Secondary prevention—reducing the risk of complications—relies on the lifestyle measures outlined above: adequate hydration, low‑purine diet, and prompt treatment of urinary stones.

Complications

If left untreated or poorly managed, the following complications may arise:

• Recurrent or obstructive kidney stones leading to chronic kidney disease (CKD) or renal failure.
• Urinary tract infections that can become pyelonephritis.
• Progressive neurocognitive decline due to ongoing metabolic stress.
• Seizure disorder worsening, potentially causing status epilepticus.
• Growth failure secondary to chronic illness and renal impairment.
• Psychiatric issues such as anxiety or depression, often linked to chronic disease burden.

When to Seek Emergency Care

Key Take‑aways

• XPRT deficiency is an autosomal recessive disorder that blocks the purine salvage pathway, leading to high xanthine levels and stone formation.
• Typical signs include developmental delays, seizures, and recurrent xanthine kidney stones.
• Diagnosis rests on biochemical testing, enzyme activity measurement, and genetic confirmation.
• Management focuses on high fluid intake, low‑purine diet, urine alkalinization, and treatment of stones and seizures.
• Regular follow‑up and multidisciplinary care are essential to prevent renal and neurologic complications.
• Genetic counseling is crucial for affected families to discuss carrier testing and reproductive options.

For personalized advice, always consult your primary care physician, a metabolic specialist, or a genetic counselor. Trusted sources for further reading include the Mayo Clinic, the CDC, the NIH, and the WHO.

```